Spring Bank Pharmaceuticals (NASDAQ: SBPH) and Auspex Pharmaceuticals (NASDAQ:ASPX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.
Insider and Institutional Ownership
28.7% of Spring Bank Pharmaceuticals shares are owned by institutional investors. 17.6% of Spring Bank Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares Spring Bank Pharmaceuticals and Auspex Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Spring Bank Pharmaceuticals||N/A||-69.68%||-44.86%|
Valuation and Earnings
This table compares Spring Bank Pharmaceuticals and Auspex Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Spring Bank Pharmaceuticals||$350,000.00||574.68||-$27.67 million||($2.58)||-6.02|
Auspex Pharmaceuticals has lower revenue, but higher earnings than Spring Bank Pharmaceuticals. Auspex Pharmaceuticals is trading at a lower price-to-earnings ratio than Spring Bank Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent ratings for Spring Bank Pharmaceuticals and Auspex Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Spring Bank Pharmaceuticals||0||1||4||0||2.80|
Spring Bank Pharmaceuticals currently has a consensus price target of $28.00, indicating a potential upside of 80.41%. Given Spring Bank Pharmaceuticals’ higher possible upside, analysts clearly believe Spring Bank Pharmaceuticals is more favorable than Auspex Pharmaceuticals.
Spring Bank Pharmaceuticals beats Auspex Pharmaceuticals on 7 of the 8 factors compared between the two stocks.
Spring Bank Pharmaceuticals Company Profile
Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases. The Company’s SB 9200 selectively activates within infected cells the cellular proteins retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company is also developing a second SMNH product candidate, SB 11285, as an immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes (STING) pathway. The Company focuses on developing SB 9200 for the treatment of chronic hepatitis B virus (HBV).
Auspex Pharmaceuticals Company Profile
Auspex Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people with movement disorders and other rare diseases, including orphan diseases. Its pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea (abnormal involuntary movements) associated with Huntington’s disease, an orphan disease, tardive dyskinesia and Tourette syndrome in the pediatric population, which is an orphan disease, as well as other orphan indications. Its lead product candidate is SD-809, which is a small molecule inhibitor of vesicular monoamine transporter 2 (VMAT2). Its other programs include SD-560, SD-1077 and SD-254.
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.